Vident Advisory, LLC Biomarin Pharmaceutical Inc Transaction History

Vident Advisory, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $11,908 - $14,755	160 Added 5.89%	2,877 $237 Million
Q1 2024 May 14, 2024	BUY	$83.81 - $99.0 $1,173 - $1,386	14 Added 0.52%	2,717 $237 Million
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $17,606 - $22,755	231 Added 9.34%	2,703 $261 Million
Q3 2023 Feb 21, 2024	SELL	$85.07 - $94.48 $19,651 - $21,824	-231 Reduced 8.55%	2,472 $219 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $210,293 - $233,554	2,472 New	2,472 $219 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Advisory, LLC with notifications on news.